If you have been reading about TB-500 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Evidence that the groups had been infiltrated by German Intelligence undercover agents has since emerged, partly through the insistence of the son of the State Counsel Siegfried Buback, who had been shot by members of the RAF in 1977.
Economically important iron deposits include: Carajás Mine in the state of Pará, Brazil, is thought to be the largest iron deposit in the world. El Mutún in Bolivia, where 10% of the world's accessible iron ore is located. Hamersley Basin is the largest iron ore deposit in Australia. Kiirunavaara in Sweden, where one of the world's largest deposits of iron ore is located. The Mesabi Iron Range is the chief iron ore mining district in the United States. Iron and steel industry Iron cycle Iron nanoparticle Iron–platinum nanoparticle Iron fertilization – proposed fertilization of oceans to stimulate phytoplankton growth Iron-oxidizing bacteria List of countries by iron production Pelletising – process of creation of iron ore pellets Rustproof iron Steel
== Signs and symptoms == Depending on where the tumor cells settle, leptomeningeal cancer can cause almost any neurological problem. The most common symptoms of leptomeningeal cancer are pain and seizures. The other symptoms may include headaches (usually associated with nausea, vomiting, light-headedness), gait difficulties from weakness or ataxia, memory problems, incontinence, and sensory abnormalities. In some cases, symptoms may include double vision, vision loss, numb chin, back pain, leg weakness, sphincter-related problems, hydrocephalus, loss of urine control, and difficulty walking. Other symptoms that are less common cranial nerve abnormalities, spinal symptoms such as limb weakness and paresthesia, and bowel and bladder dysfunction. Diplopia is the most common symptom of cranial nerve dysfunction. Trigeminal sensory or motor loss, cochlear dysfunction, and optic neuropathy are also common findings. Spinal signs and symptoms include weakness, dermatomal or segmental sensory loss, and pain in the neck, back, or following radicular patterns. 3 affected domains of neurological function:
== Return, illness, and death == In 1999, the Panamanian government had sought the extradition of Noriega from the U.S., as he had been tried in absentia and found guilty of murder in Panama in 1995. After Noriega was imprisoned in France, Panama asked the French government to extradite Noriega so he could face trial for human rights violations in Panama. The French government had previously stated that extradition would not happen before the case in France had run its course. On September 23, 2011, a French court ordered a conditional release for Noriega to be extradited to Panama on October 1, 2011. Noriega was extradited to Panama on December 11, 2011, and incarcerated at El Renacer prison to serve the sentences, totalling 60 years, that he had accumulated in absentia for crimes committed during his rule. On February 5, 2012, Noriega was moved to Hospital Santo Tomás in Panama City because of high blood pressure and a brain hemorrhage. He remained in the hospital for four days before being returned to prison. It was announced on March 21, 2012, that Noriega had been diagnosed with a brain tumor, which was later revealed to have been benign. On January 23, 2017, he was released from prison and placed under house arrest to prepare for surgery that would remove the tumor. On March 7, 2017, he suffered a brain hemorrhage during surgery which left him in critical condition in the intensive care unit of Hospital Santo Tomás. Noriega died on May 29, 2017, at the age of 83.
== External links == Media related to Phyllostachys nigra at Wikimedia Commons Data related to Phyllostachys nigra at Wikispecies "Phyllostachys nigra". Integrated Taxonomic Information System. John Lindley (1835). "Description of Bambusa nigra". The Penny Cyclopædia of the Society for the Diffusion of Useful Knowledge. Vol. 3. p. 357.
Sources: en.wikipedia.org
constitutive expression 1. The continuous transcription of a gene, as opposed to facultative expression, in which a gene is only transcribed as needed. A gene that is transcribed continuously is called a constitutive gene. 2. A gene whose expression depends only on the efficiency of its promoter in binding RNA polymerase, and not on any transcription factors or other regulatory elements which might promote or inhibit its transcription.
== Commercialisation == Commercial disinfection applications remained elusive for a long time after the discovery of hypochlorous acid because the stability of its solution in water is difficult to maintain. The active compounds quickly deteriorate back into salt water, losing the solution its disinfecting capability, which makes it difficult to transport for wide use. It is less commonly used as a disinfectant compared to bleach and alcohol due to cost, despite its stronger disinfecting capabilities. Technological developments have reduced manufacturing costs and allow for manufacturing and bottling of hypochlorous acid water for home and commercial use. However, most hypochlorous acid water has a short shelf life. Storing away from heat and direct sunlight can help slow the deterioration. The further development of continuous flow electrochemical cells has been implemented in new products, allowing the commercialisation of domestic and industrial continuous flow devices for the in-situ generation of hypochlorous acid for disinfection purposes.
On 7 April 2009, The Pentagon announced they spent more than $100 million in the last six months responding to and repairing damage from cyber attacks and other computer network problems. On 1 April 2009, U.S. lawmakers pushed for the appointment of a White House cyber security "czar" to dramatically escalate U.S. defenses against cyber attacks, crafting proposals that would empower the government to set and enforce security standards for private industry for the first time. On 9 February 2009, the White House announced that it will conduct a review of the country's cyber security to ensure that the Federal government of the United States cyber security initiatives are appropriately integrated, resourced and coordinated with the United States Congress and the private sector. In the wake of the 2007 cyberwar waged against Estonia, NATO established the Cooperative Cyber Defence Centre of Excellence (CCD CoE) in Tallinn, Estonia, in order to enhance the organization's cyber defence capability. The center was formally established on 14 May 2008, and it received full accreditation by NATO and attained the status of International Military Organization on 28 October 2008. Since Estonia has led international efforts to fight cybercrime, the United States Federal Bureau of Investigation says it will permanently base a computer crime expert in Estonia in 2009 to help fight international threats against computer systems.
=== Other === An engineer replaced a woodpecker-damaged feed horn of a high-power microwave antenna, a 15-meter dish at an Earth station of a television network, using a cherry picker. After finishing, he sent his technician to power up the transmitter, and attempted to lower the cherry picker down. The engine failed and the engineer was stuck next to the antenna, outside of its main lobe but well within the first sidelobe. The technician, unaware that the engineer was still close to the antenna, powered it up. The engineer was exposed to an intense microwave field for about three minutes, until the error was realized. There were no immediate symptoms; the next morning the engineer detected blood and solid matter in his urine, and visited a doctor, who found blood in stool and massive bowel adhesions. The engineer's medical problems lasted for many years.
=== Polycythemia in adults === Different diseases or conditions can cause polycythemia in adults. These processes are discussed in more detail in their respective sections below. Relative polycythemia, also known as pseudopolycythemia, is not a true increase in the number of red blood cells or hemoglobin in the blood, but rather an elevated laboratory finding caused by reduced blood plasma (hypovolemia, cf. dehydration). Relative polycythemia is often caused by loss of body fluids, such as through burns, dehydration, and stress. A specific type of relative polycythemia is Gaisböck syndrome; in this syndrome, primarily occurring in obese men, hypertension causes a reduction in plasma volume, resulting in (amongst other changes) a relative increase in red blood cell count. If relative polycythemia is deemed unlikely because the patient has no other signs of hemoconcentration and has sustained polycythemia without clear loss of body fluids, the patient likely has absolute or true polycythemia. Absolute or true polycythemia (also erythrocytosis) can be split into two categories:
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.